Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma.

Related Articles

Pharmacogenomics of genes involved in antifolate drug response and toxicity in osteosarcoma.

Expert Opin Drug Metab Toxicol. 2017 Mar;13(3):245-257

Authors: Hattinger CM, Tavanti E, Fanelli M, Vella S, Picci P, Serra M

Abstract
INTRODUCTION: Antifolates are structural analogs of folates, which have been used as antitumor drugs for more than 60 years. The antifolate drug most commonly used for treating human tumors is methotrexate (MTX), which is utilized widely in first-line treatment protocols of high-grade osteosarcoma (HGOS). In addition to MTX, two other antifolates, trimetrexate and pemetrexed, have been tested in clinical settings for second-line treatment of recurrent HGOS with patients unfortunately showing modest activity. Areas covered: There is clinical evidence which suggsest that, like other chemotherapeutic agents, not all HGOS patients are equally responsive to antifolates and do not have the same susceptibility to experience adverse drug-related toxicities. Here, we summarize the pharmacogenomic information reported so far for genes involved in antifolate metabolism and transport and in MTX-related toxicity in HGOS patients. Expert opinion: Identification and validation of genetic biomarkers that significantly impact clinical antifolate treatment response and related toxicity may provide the basis for a future treatment modulation based on the pharmacogenetic and pharmacogenomic features of HGOS patients.

PMID: 27758143 [PubMed - indexed for MEDLINE]

http://ift.tt/2dtACCu